Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441519 | 0.92 | DGAT1 (0.86) | DGAT1 | |
| SCHEMBL2491814 | 0.91 | DGAT1 (0.74) | DGAT1 | |
| SCHEMBL2491777 | 0.91 | DGAT1 (0.79) | DGAT1 | |
| SCHEMBL2545664 | 0.89 | DGAT1 (0.76) | DGAT1 | |
| SCHEMBL2513899 | 0.87 | DGAT1 (0.81) | DGAT1 | |
| SCHEMBL3636503 | 0.86 | DGAT1 (0.84) | DGAT1 | |
| SCHEMBL2493895 | 0.85 | DGAT1 (0.78) | DGAT1 | |
| SCHEMBL27951986 | 0.85 | DGAT1 (0.80) | DGAT1 | |
| SCHEMBL2515004 | 0.85 | DGAT1 (0.80) | DGAT1 | |
| SCHEMBL13229240 | 0.85 | DGAT1 (1.00) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | claimed |
| CN-102245024-A | Inhibitors of diacylglycerol aclytransferase | VIA PHARMACEUTICALS INC | 2011-11-16 | — | — | CN | claimed |
| EP-2378878-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Via Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | claimed |
| WO-2010077861-A1 | INHIBITORS OF DIACYLGLYCEROL ACLYTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-07-08 | — | — | WO | claimed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | claimed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| CN-102245024-A | Inhibitors of diacylglycerol aclytransferase | VIA PHARMACEUTICALS INC | 2011-11-16 | — | — | CN | disclosed |
| EP-2378878-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Via Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010077861-A1 | INHIBITORS OF DIACYLGLYCEROL ACLYTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | DGAT2, DGAT1, ACAT2 | DGAT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.